These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 15447739)

  • 1. In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists.
    Hancock AA; Diehl MS; Faghih R; Bush EN; Krueger KM; Krishna G; Miller TR; Wilcox DM; Nguyen P; Pratt JK; Cowart MD; Esbenshade TA; Jacobson PB
    Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):144-52. PubMed ID: 15447739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist.
    Hancock AA; Bennani YL; Bush EN; Esbenshade TA; Faghih R; Fox GB; Jacobson P; Knourek-Segel V; Krueger KM; Nuss ME; Pan JB; Shapiro R; Witte DG; Yao BB
    Eur J Pharmacol; 2004 Mar; 487(1-3):183-97. PubMed ID: 15033391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.
    Hancock AA; Diehl MS; Fey TA; Bush EN; Faghih R; Miller TR; Krueger KM; Pratt JK; Cowart MD; Dickinson RW; Shapiro R; Knourek-Segel VE; Droz BA; McDowell CA; Krishna G; Brune ME; Esbenshade TA; Jacobson PB
    Inflamm Res; 2005 Apr; 54 Suppl 1():S27-9. PubMed ID: 15928821
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
    Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
    Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity.
    Morini G; Comini M; Rivara M; Rivara S; Bordi F; Plazzi PV; Flammini L; Saccani F; Bertoni S; Ballabeni V; Barocelli E; Mor M
    Bioorg Med Chem; 2008 Dec; 16(23):9911-24. PubMed ID: 18976927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [125I]iodoproxyfan and related compounds: a reversible radioligand and novel classes of antagonists with high affinity and selectivity for the histamine H3 receptor.
    Stark H; Purand K; Hüls A; Ligneau X; Garbarg M; Schwartz JC; Schunack W
    J Med Chem; 1996 Mar; 39(6):1220-6. PubMed ID: 8632428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds.
    Mikó T; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2003 Apr; 46(8):1523-30. PubMed ID: 12672253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of chiral N-alkylcarbamates as new leads for potent and selective H3-receptor antagonists: synthesis, capillary electrophoresis, and in vitro and oral in vivo activity.
    Sasse A; Kiec-Kononowicz K; Stark H; Motyl M; Reidemeister S; Ganellin CR; Ligneau X; Schwartz JC; Schunack W
    J Med Chem; 1999 Feb; 42(4):593-600. PubMed ID: 10052966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
    Sun M; Zhao C; Gfesser GA; Thiffault C; Miller TR; Marsh K; Wetter J; Curtis M; Faghih R; Esbenshade TA; Hancock AA; Cowart M
    J Med Chem; 2005 Oct; 48(20):6482-90. PubMed ID: 16190774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands.
    Tedford CE; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Handley MK; Yates SL
    J Pharmacol Exp Ther; 1999 May; 289(2):1160-8. PubMed ID: 10215700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists.
    Mikó T; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    Bioorg Med Chem; 2004 May; 12(10):2727-36. PubMed ID: 15110854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
    Esbenshade TA; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Fox GB; Faghih R; Bennani YL; Williams M; Hancock AA
    J Pharmacol Exp Ther; 2003 Jun; 305(3):887-96. PubMed ID: 12606603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel carbamates as potent histamine H3 receptor antagonists with high in vitro and oral in vivo activity.
    Stark H; Purand K; Ligneau X; Rouleau A; Arrang JM; Garbarg M; Schwartz JC; Schunack W
    J Med Chem; 1996 Mar; 39(5):1157-63. PubMed ID: 8676353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Furoxan analogues of the histamine H3-receptor antagonist imoproxifan and related furazan derivatives.
    Tosco P; Bertinaria M; Di Stilo A; Cena C; Sorba G; Fruttero R; Gasco A
    Bioorg Med Chem; 2005 Aug; 13(15):4750-9. PubMed ID: 15946850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
    Zhao C; Sun M; Bennani YL; Gopalakrishnan SM; Witte DG; Miller TR; Krueger KM; Browman KE; Thiffault C; Wetter J; Marsh KC; Hancock AA; Esbenshade TA; Cowart MD
    J Med Chem; 2008 Sep; 51(17):5423-30. PubMed ID: 18683917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Search for novel leads for histamine H3-receptor antagonists: oxygen-containing derivatives.
    Stark H; Hüls A; Ligneau X; Arrang JM; Schwartz JC; Schunack W
    Pharmazie; 1997 Jul; 52(7):495-500. PubMed ID: 9266588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists.
    Ali SM; Tedford CE; Gregory R; Handley MK; Yates SL; Hirth WW; Phillips JG
    J Med Chem; 1999 Mar; 42(5):903-9. PubMed ID: 10072687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
    Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R
    J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dibasic biphenyl H3 receptor antagonists: Steric tolerance for a lipophilic side chain.
    Bordi F; Rivara S; Dallaturca E; Carmi C; Pala D; Lodola A; Vacondio F; Flammini L; Bertoni S; Ballabeni V; Barocelli E; Mor M
    Eur J Med Chem; 2012 Feb; 48():214-30. PubMed ID: 22222138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.